文献速递脊柱关节炎

银屑病关节炎患者达到MDA后停用依奇珠单抗的随机双盲撤药研究

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
PubMed 文献 · Arthritis Rheumatol · 2021-08-06

SPIRIT-P3研究纳入394例未用过生物制剂的银屑病关节炎患者,开放标签依奇珠单抗治疗36周后,158例(40%)达到持续MDA并随机1:1撤药(安慰剂)或继续治疗。撤药组复发更快(中位22.3周 vs 不可估计,P<0.0001),复发率85% vs 38%;撤药后复发者再治疗中位4.1周重新达到MDA(64/67例,96%)。

要点

  • 达到持续MDA的PsA患者撤用依奇珠单抗后复发风险显著高于继续治疗。
  • 撤药组85%复发,继续治疗组38%复发,中位复发时间22.3周 vs 不可估计。
  • 撤药后复发者再治疗多数可重新达到MDA,中位时间4.1周。

核心结论

  • 在未用过生物制剂的PsA患者中,继续依奇珠单抗治疗在维持低疾病活动度方面优于撤药。
  • 撤药后复发者再治疗可恢复疾病控制。

研究设计与样本

  • SPIRIT-P3为多中心、随机、双盲撤药研究,纳入未用过生物制剂的成人PsA患者。
  • 患者先接受开放标签依奇珠单抗治疗36周(第0周160mg,之后每2周80mg)。
  • 持续MDA超过3个月者在第36至64周按1:1随机撤药(安慰剂)或继续依奇珠单抗每2周至第104周。
  • 共394例接受开放标签治疗,158例(40%)达到持续MDA并随机(安慰剂组79例,继续治疗组79例)。

主要发现

  • 撤药组疾病复发更快,中位22.3周(95%CI 16.1-28.3),继续治疗组中位不可估计(P<0.0001)。
  • 撤药组67例(85%)复发,继续治疗组30例(38%)复发。
  • 撤药后复发者再治疗达到MDA的中位时间为4.1周(95%CI 4.1-4.3)。
  • 撤药后复发的67例中64例(96%)再治疗重新达到MDA。
  • 安全性与其他依奇珠单抗已知安全性特征一致。

关键数值与推荐

  • 持续MDA定义为MDA维持超过连续3个月。
  • 主要疗效终点为随机化患者的复发时间(MDA丧失)。

临床怎么用

  • 对已达到持续MDA的PsA患者,继续依奇珠单抗治疗比撤药更能维持低疾病活动度。
  • 若因故中断治疗,复发后再用依奇珠单抗可能恢复疾病控制。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis (PsA) in whom minimal disease activity (MDA) has been achieved after open-label ixekizumab treatment. METHODS: SPIRIT-P3 was a multicenter, randomized, double-blind withdrawal study of biologic treatment-naive adult patients with PsA who were treated with open-label ixekizumab for 36 weeks (160 mg at week 0, then 80 mg every 2 weeks). Patients in whom MDA was sustained for >3 consecutive months were randomized 1:1, between weeks 36 and 64, to undergo blinded withdrawal of ixekizumab treatment (placebo) or to continue ixekizumab treatment every 2 weeks up to week 104. The primary efficacy end point was time to relapse (loss of MDA) for randomized patients. Patients who experienced a relapse were re-treated with ixekizumab every 2 weeks up to week 104. RESULTS: A total of 394 patients were enrolled and received open-label ixekizumab every 2 weeks. Of those patients, 158 (40%) achieved sustained MDA and were randomized to undergo withdrawal of ixekizumab treatment (placebo every 2 weeks; n = 79) or to continue ixekizumab treatment every 2 weeks (n = 79). Disease relapse occurred more rapidly with treatment withdrawal (median 22.3 weeks [95% confidence interval (95% CI) 16.1-28.3]) compared to those who continued treatment with ixekizumab (median not estimable; P < 0.0001). Sixty-seven patients (85%) compared to 30 patients (38%) experienced relapse in the placebo group and the continued treatment group, respectively. Median time to achieving MDA again with re-treatment was 4.1 weeks (95% CI 4.1-4.3); in 64 of 67 patients (96%) who experienced relapse with treatment withdrawal, MDA was achieved again with re-treatment. Safety was consistent with the known safety profile for ixekizumab. CONCLUSION: Continued ixekizumab therapy is superior to ixekizumab withdrawal in maintaining low disease activity in biologic treatment-naive patients with PsA. Re-treatment with ixekizumab following a relapse may restore disease control in cases of treatment interruption.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Coates LC, Pillai SG, Tahir H, et al. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study. Arthritis Rheumatol. 2021. PMID: 33682378. doi:10.1002/art.41716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。